Filing Flows › Vistagen Therapeutics (VTGN) › Q4 FY26
Vistagen Therapeutics (VTGN) Q4 FY26 earnings results (fourth quarter fiscal 2026)
10-K filed Jun 15, 2026
Vistagen Therapeutics (VTGN) reported revenue of $465K for the fourth quarter fiscal 2026 (Q4 FY26) and +53% from the quarter before.
Vistagen Therapeutics, Q4 FY26: revenue $465K, net loss $16.3M, operating cash flow −$16.2M. The chart follows the revenue to costs, profit and cash.
| Q4 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $465K | +53% | — |
| Operating profit | −$16.7M | — | — |
| Net earnings | −$16.3M | — | — |
| Operating cash flow | −$16.2M | — | — |
What changed
Revenue was $465K in Q4 FY26, up 53% from the previous quarter.
Operating costs exceeded revenue by $16.7M, an operating margin of -3595.1%. The quarter ended with a net loss of $16.3M, narrower than the previous quarter's $18.9M loss.
Operating cash flow was −$16.2M. Non-cash charges added back $52K of depreciation and amortization and $889K of share-based compensation. Working capital and other items used $867K.
Questions
What was Vistagen Therapeutics' revenue in the fourth quarter fiscal 2026?
Vistagen Therapeutics (VTGN) reported revenue of $465K for the fourth quarter fiscal 2026 (Q4 FY26) and +53% from the quarter before.